6 Comments

i really really really love the way you breakdown the thesis by your 16 points of quality, thank you!

Expand full comment

Thank you very much, Paul. It's an honor to write for you!

Expand full comment

Loved the systematic way you analysed the stock using your 18-20 valuation parameters. My question is - while analysing any stock, should we not also look at close competitors across the same valuation parameters and also do a macro analysis of the industry as a whole?

Expand full comment

Fair point. We try to cover this in point 4. Is the company active in an attractive end market?

Let's focus a bit more on competitors in the next article

Expand full comment

Like Paul Martin here, I also really like the breakdown of the qualitative and quantitative metrics. It's a great framework!

That said, I typically stay away from anything related to healthcare, biomedical, pharmaceutical, etc industries because all of that is way over my head and way outside my circle of competence. I have no idea what it takes for something like a drug, a food, a device, etc to be successful and I also don't know what would cause a failure. This space is often heavily regulated by industry and government agencies that I also don't understand.

Good luck to all! 🙂

Expand full comment

Fair pont, Boris! I always love your comments!

Still figuring out the best way to make Compounding Dividends work. If you have suggestions, feel free to share them!

Expand full comment